Why the study?
The optimal choice, combination, and duration of antithrombotic therapy in patients with CCS undergoing PCI remain a clinical conundrum following recently published new and revised 2024 ESC guideline recommendations.
This review highlights the updated 2024 ESC guideline recommendations for optimizing antithrombotic therapy in patients with chronic coronary syndrome undergoing PCI.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to 2024 ESC antithrombotic updates for CCS-PCI; leaves open real-world validation against expert consensus.
Antithrombotic therapy represents the mainstay of the pharmacological treatment in patients with chronic coronary syndrome (CCS) undergoing percutaneous coronary intervention (PCI). The optimal choice, combination, and duration of antithrombotic therapy represent still a clinical conundrum requiring a critical assessment of patient comorbidities, clinical presentation, and PCI features. The 2024 European Society of Cardiology (ESC) guidelines for the management of patients with CCS have been recently published encompassing new and revised recommendations on antithrombotic therapy. The scope of this manuscript is to provide a focus on the key recommendations on antithrombotic therapy of the 2024 ESC guidelines. Furthermore, we will provide an overview of differences and similarities between the latest ESC recommendations and statements on oral antithrombotic regimens in CCS patients from a recent European expert consensus document.
No takes yet. Share an insight, caveat, or question.
Landi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: